CIAM
CTMX icon

Caitong International Asset Management’s CytomX Therapeutics CTMX Stock Holding History

Caitong International Asset Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.75K Sell
1,649
-3,041
-65% -$15.4K ﹤0.01% 1102
2025
Q4 		$20K Buy
4,690
+4,001
+581% +$15.2K ﹤0.01% 984
2025
Q3 		$2.2K Sell
689
-967
-58% -$2.18K ﹤0.01% 1368
2025
Q2 		$3.76K Buy
+1,656
New +$2.67K ﹤0.01% 1137

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Caitong International Asset Management's CTMX Position: Q1 2026 in Review

Caitong International Asset Management reduced its CytomX Therapeutics (CTMX) stake by 65% in Q1 2026, selling an estimated $15.4K and leaving 1,649 shares worth $7.75K. The position accounts for ﹤0.01% of the portfolio, ranked #1102.

Caitong International Asset Management first reported a position in CTMX in Q2 2025 and has held it in 4 quarters since. The position peaked at $20K in Q4 2025. 179 funds tracked by Wall St. Rank hold CTMX as of Q1 2026.

  • Caitong International Asset Management held 1,649 shares of CytomX Therapeutics worth $7.75K as of Q1 2026.
  • Caitong International Asset Management sold 3,041 CytomX Therapeutics shares in Q1 2026, an estimated $15.4K.
  • CytomX Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q1 2026, its #1102 holding.
  • Caitong International Asset Management first reported a position in CytomX Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Caitong International Asset Management's CytomX Therapeutics position peaked at $20K in Q4 2025.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.